Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours

BACKGROUND: Axitinib, a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors, enhanced the efficacy of chemotherapy in human xenograft tumour models. This phase I study investigated the safety, tolerability, pharmacokinetics and antitumour activity of axit...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Martin, L P, Kozloff, M F, Herbst, R S, Samuel, T A, Kim, S, Rosbrook, B, Tortorici, M, Chen, Y, Tarazi, J, Olszanski, A J, Rado, T, Starr, A, Cohen, R B
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2012
Matèries:
Clinical Study
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3494424/
https://ncbi.nlm.nih.gov/pubmed/22996612
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.407
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars